Alzamend Neuro (ALZN) Common Equity (2020 - 2026)

Alzamend Neuro has disclosed Common Equity across 7 years of filings, most recently posting $733211.0 for Q2 2026.

• In Q2 2026, Common Equity fell 81.52% year-over-year to $733211.0; the TTM figure through Apr 2026 stood at $733211.0 (down 81.52% YoY), while the FY2026 annual figure was $733211.0, down 81.52% from the prior year.
• Common Equity came in at $733211.0 for Q2 2026 at Alzamend Neuro, down from $2.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $13.4 million in Q2 2022 to a low of -$4.3 million in Q1 2024.
• Average Common Equity over 5 years is $3.7 million, with a median of $3.6 million recorded in 2024.
• Year-over-year, Common Equity jumped 1023.04% in 2022 and tumbled 973.96% in 2024.
• Over 5 years, Common Equity stood at $8.8 million in 2022, then plunged by 130.53% to -$2.7 million in 2023, then soared by 239.91% to $3.8 million in 2024, then grew by 16.55% to $4.4 million in 2025, then plunged by 83.24% to $733211.0 in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $733211.0 in Q2 2026, $2.2 million in Q1 2026, and $4.4 million in Q4 2025.